bronchial secretion

Regular, daily drainage to remove bronchial secretions is a routine part of treatment.

Other symptoms include increased sweating, salivation, bronchial secretions along with miosis.

The endpoint of atropine administration is the clearing of bronchial secretions.

Immunoglobulin-A is secreted in the bronchial secretion and protects against respiratory infections.

It has been shown to increase the proportion of serous bronchial secretion, making it more easily expectorated.

Mucolytic agents like bromhexine and carbocisteine help bring out excessive bronchial secretions more easily by coughing.

Carbocisteine should not be used with antitussives (cough suppressants) or medicines that dry up bronchial secretions.

Treatment is aimed at controlling infections and bronchial secretions, relieving airway obstruction, and preventing complications.

Clearance of bronchial secretions is essential for good pulmonary health and can help limit injury from acute and chronic lung infections.

Children and adults with increased bronchial secretions can benefit from routine chest therapy using the manual method, an a cappella device or a chest physiotherapy vest.

Besides its antitussive action, it helps to clear the respiratory tract, since it increases the quantity of secretion and thins bronchial secretion.

Other individuals with A-T have difficulty with taking deep breaths and may have an ineffective cough, which makes it difficult to clear oral and bronchial secretions.

A humectant and expectorant, terpin hydrate works directly on the bronchial secretory cells in the lower respiratory tract to liquefy and facilitate the elimination of bronchial secretions.

Treatment of bronchiectasis includes controlling infections and bronchial secretions, relieving airway obstructions, removal of affected portions of lung by surgical removal or artery embolization and preventing complications.

Muscarine poisoning is characterized by miosis, blurred vision, increased salivation, excessive sweating, lacrimation, bronchial secretions, bronchoconstriction, bradycardia, abdominal cramping, increased gastic acid secretion, diarrhea and polyuria.

In people who have decreased lung reserve and a weak cough, use of an insufflator-exsufflator (cough-assist) device may be useful as a maintenance therapy or during acute respiratory illnesses to help remove bronchial secretions from the upper airways.

When there is expression of muscarinic overstimulation due to excess acetylcholine at muscarinic acetylcholine receptors symptoms of visual disturbances, tightness in chest, wheezing due to bronchoconstriction, increased bronchial secretions, increased salivation, lacrimation, sweating, peristalsis, and urination can occur.

A great deal of emphasis is placed on post-operative pulmonary toilet because the incisional pain associated with thoracotomy leads to a decreased ability of patients to cough and clear bronchial secretions, which in turn leads to an increased risk of persistent atelectasis (collapsed areas of lung) or pneumonia.

Working as a nonselective muscarinic acetylcholinergic antagonist, atropine increases firing of the sinoatrial node (SA) and conduction through the atrioventricular node (AV) of the heart, opposes the actions of the vagus nerve, blocks acetylcholine receptor sites, and decreases bronchial secretions.

Symptoms of exposure to this type of compound include cholinesterase inhibition, miosis, frontal headache, increased bronchial secretion, nausea, vomiting, sweating, abdominal cramps, diarrhea, lacrimation, increased salivation, bradycardia, cyanosis and muscular twitching of the eyelids, tongue, face and neck, possibly progressing to convulsions.